Welcome to our dedicated page for Cybin SEC filings (Ticker: CYBN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
From dosing protocols in Phase II trials to patent claims on deuterated psilocybin, Cybin’s SEC paperwork demands deep scientific and regulatory fluency. If you have ever scrolled through a 300-page prospectus searching for trial endpoints or waited for an 8-K that confirms a breakthrough-therapy meeting, you know the pain. Stock Titan solves it: our AI instantly converts dense disclosures into plain-English briefs, surfaces red-flag risks, and links each note back to the original page so you can verify facts in seconds. In short, consider this “Cybin SEC filings explained simply.”
Whether you need the full “Cybin annual report 10-K simplified” or want “Cybin quarterly earnings report 10-Q filing” highlights, we cover every form the moment it hits EDGAR. Real-time alerts track “Cybin Form 4 insider transactions real-time,” while interactive dashboards group every “Cybin insider trading Form 4 transactions” by executive and clinical milestone. Our engine delivers “Cybin 8-K material events explained,” maps R&D spend, and even decodes the “Cybin proxy statement executive compensation” tables so you see option grants in context. The AI-powered summaries update with each amendment, ensuring you are always reading the most current version.
Use the data the way professionals do: compare quarter-over-quarter trial costs, monitor “Cybin executive stock transactions Form 4” before key readouts, and share “Cybin earnings report filing analysis” with colleagues in one click. Still “understanding Cybin SEC documents with AI”? Our platform overlays definitions, creates custom peer benchmarks, and archives every footnote for audit trails. From first clinical IND to commercial launch, Stock Titan equips you with comprehensive coverage, expert commentary, and the clarity needed to make informed decisions faster than the market.
Cybin Inc. (CYBN) received a Schedule 13G showing that Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin collectively report beneficial ownership of 3,072,250 common shares, representing 6.09% of the class as of the reported date.
The filing lists shared voting and dispositive power over 3,072,250 shares and no sole voting or dispositive power. The ownership calculation references 50,431,381 shares, derived from 49,894,131 shares outstanding as of October 28, 2025 plus 537,250 warrants that are exercisable subject to a 9.99% Maximum Percentage beneficial ownership cap. The certification states the securities were not acquired to change or influence control.
Cybin Inc. received an amended Schedule 13G filing reporting that Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin collectively beneficially own 1,000,000 common shares, equal to 3.97% of the class. The Date of Event Which Requires Filing is 09/30/2025.
The reporting persons have shared voting and dispositive power over 1,000,000 shares and no sole voting or dispositive power. The filing indicates ownership of 5 percent or less of the class and includes a certification that the securities were not acquired to change or influence control of the issuer.
For context, the percent ownership is based on 25,188,217 common shares outstanding as of September 16, 2025, as cited from the issuer’s F-10. Information is stated as of October 29, 2025.
Cybin Inc. (CYBN) filed a new Form D for an exempt offering under Rule 506(b). The notice covers stock options exercisable at CAD$8.39 per share, vesting in eight quarterly tranches beginning December 31, 2025.
Total amount sold is $0 USD, with $601,865 USD remaining to be sold. The company notes the total represents the maximum potential proceeds from option exercises. The filing lists a Date of First Sale: October 1, 2025, and reports $0 in finders’ fees. The issuer is incorporated in Ontario, Canada and identifies its industry as health care/biotechnology.
CYBIN INC. filed a Form D for a new, Regulation D exempt offering under Rule 506(b) to register up to $120,070 USD in potential proceeds, which represents the maximum amount potentially received from the exercise of stock options. No proceeds have been sold yet and total remaining to be sold is $120,070 USD. The securities consist primarily of stock options exercisable at CAD$11.00 per share that vest in eight quarterly tranches beginning September 30, 2025. The offering is intended to last more than one year. No sales commissions or finders’ fees were disclosed and no proceeds are allocated to named executives or directors. One investor is reported and one non-accredited investor has participated.
FAQ
What is the current stock price of Cybin (CYBN)?
What is the market cap of Cybin (CYBN)?
